The Meals and Drug Administration (FDA) has granted 510(ok) clearance for FemChec®, a modality that generates pure distinction to be used in ultrasound imaging of fallopian tubes. This imaging might doubtlessly be utilized to substantiate the success of FemBloc®, a non-surgical strategy to everlasting contraception that’s presently being evaluated in a scientific trial.
Utilizing an intrauterine catheter, clinicians can make use of FemChec to offer a steady distinction media stream of alternating saline and air to reinforce ultrasound visualization of the fallopian tubes with or with out the uterine cavity, in accordance with Femasys, the developer of FemChec and FemBloc.
The just lately FDA-cleared FemChec®, which generates pure distinction to be used in ultrasound imaging of fallopian tubes, might doubtlessly play a key diagnostic function in confirming the outcomes of a non-surgical strategy to everlasting contraception (FemBloc®) that’s presently being evaluated in a scientific trial. (Photograph courtesy of Adobe Inventory.)
The corporate stated the mix of pure distinction and ultrasound might present a viable different to conventional X-ray and corresponding radiation publicity for evaluating fallopian tubes.
“FemChec is a vital a part of our suite of ladies’s well being merchandise because it fortifies our place to offer secure and technologically superior diagnostic and therapeutic options addressing girls’s well being care wants,” famous Kathy-Lee Sepsick, the chief govt officer and founding father of Femasys.
